阿托伐他汀治疗急性前循环脑梗死临床评价

目的探讨阿托伐他汀治疗急性前循环脑梗死的临床疗效及对患者血清胶质纤维酸性蛋白(GFAP)、肿瘤坏死因子-α(TNF-α)和单核细胞趋化蛋白-1(MCP-1)水平的影响。方法选取医院2016年8月至2018年8月收治的急性前循环脑梗死患者80例,按随机数字表法分为试验组和对照组,各40例。两组患者均予常规治疗,并静脉滴注胞二磷胆碱注射液,试验组患者加服阿托伐他汀钙片。结果试验组有效率为95. 00%,显著高于对照组的72. 50%(P <0. 05)。与治疗前比较,两组患者治疗后的美国国立卫生研究院卒中量表(NIHSS)评分和总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C),以及GFAP,TNF-α,MCP-1水平均显著降低,日常生活能力量表(ADL)评分及高密度脂蛋白胆固醇(HDL-C)水平均显著升高,且试验组患者上述指标改善程度均显著优于对照组(P <0. 05)。对照组出现恶心呕吐、头晕各1例,试验组出现恶心1例,对症治疗后症状均消失。结论阿托伐他汀治疗急性前循环脑梗死疗效较好,可优化血脂指标,降低GFAP,TNF-α,MCP-1水平。

Atorvastatin in Treating Acute Anterior Circulation Cerebral Infarction

Objective To investigate the application of atorvastatin in the treatment of acute anterior circulation cerebral infarction and its effect on serum levels of glial fibrillary acidic protein( GFAP),tumor necrosis factor-alpha( TNF-α) and monocyte chemoattractant protein-1( MCP-1). Methods Eighty patients with acute anterior circulation cerebral infarction admitted from August 2016 to August 2018 were divided into the experimental group and the control group according to the random number table method,40 cases in each group. Both groups were given routine clinical treatment and intravenous injection of citicoline,while patients in the experimental group were given atorvastatin calcium on the basis of the control group. Results The effective rate in the experimental group was95. 00%,which was significantly higher than 72. 50% in the control group( P < 0. 05). After treatment,the National Institutes of Health Stroke Scale( NIHSS) scores,the levels of total cholesterol( TC),low density lipoprotein cholesterol( LDL-C),GFAP,TNF-α and MCP-1 significantly decreased,and the activity of daily living( ADL) scores and high-density lipoprotein cholesterol( HDL-C) levels increased in both groups,and the improvements in the experimental group were significantly better than those in the control group( P < 0. 05). In the control group,there was 1 case of nausea and vomiting,1 case of dizziness;in the experimental group,there was 1 case of nausea. After corresponding treatment,their symptoms disappeared. Conclusion Atorvastatin in treating patients with acute anterior circulation cerebral infarction has good clinical efficacy,which can optimize the blood lipid index,reduce the levels of GFAP,TNF-αand MCP-1.